Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Pfenex Inc. (NYSE MKT: PFNX), a ... biosimilar therapeutics including high value and difficult to ... 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host ... and provide a business update. A press release outlining ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular ... William S. Marth , AMRI,s President and Chief ... Merrill Lynch 2015 Health Care Conference on Wednesday, May ... live audio webcast of the presentation can be accessed ... The webcast will be archived for ...
(Date:4/30/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, announced plans to release ... on May 7, 2015 after the close of the ... a conference call at 4:30 p.m. Eastern Time on ... results. During the conference call, material information concerning the ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology ... capacity and production capability to serve biotechnology pharmaceutical ... service fulfillment continues to drive Nitto Avecia to ... capacities. , In Fall 2014, Nitto ... equipment at its Milford, MA facility, which is ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... /PRNewswire-FirstCall/-- MINRAD,International, Inc. (Amex: BUF ) announced today that ... quarter 2008 financial results,on Tuesday, May 13, 2008 at 4:30 ... to the call on Tuesday, May 13, 2008., The ... (866) 866-1333.,The international call in number is (404) 260-1421., ...
... 8 BioSpace, the world,s leading,online bioscience ... company, unveiled,this morning the 2008 Bio NC(TM) ... Carolina., (Photo: http://www.newscom.com/cgi-bin/prnh/20080508/CLTH087 ), ... This unique campaign highlights the biotechnology, pharmaceutical ...
... ("AIT"),announced today that the company,s Biochemimarker(TM) Discovery Products,will ... from autistic children,for metabolic biochemical assessment when they ... constructed at The Children,s Institute,in Pittsburgh, PA. Scott ... will lead a team of scientists for this ...
Cached Biology Technology:MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008 2BioSpace Launches 6th Edition of Bio NC(TM) Hotbed Campaign 2Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism 2
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... emit deadly venom from tentacles that can reach ten feet in ... been of interest to scientists and to the public. Yet little ... the animal tree of life. In a paper published November ... researchers Allen Collins, Bastian Bentlage and Cheryl Lewis Ames of the ...
... Scientists in China are reporting discovery of unusual liver ... long-standing mystery of why the hepatitis B virus (HBV) sexually ... been published online in ACS, Journal of Proteome Research ... and colleagues note that chronic hepatitis B seems to progress ...
... A new generation of "green" automobile tires that can ... their way through the research pipeline. The new tires could ... a car,s fuel economy. That,s the topic of the cover ... (C&EN) ACS, weekly newsmagazine. C&EN Senior Editor Alexander ...
Cached Biology News:Scientists unravel evolution of highly toxic box jellyfish 2Scientists unravel evolution of highly toxic box jellyfish 3
... The DMW143 taken from the SMZ line ... environments of production and testing. It is available ... base (FBGG) or a space-saving compact base (N2GG). ... computer, TV and a projector all at the ...
... Odyssey images are easily imported for data analysis , ... ... , Extensive background and signal options to optimize, ... results , ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
Biology Products: